Document is current
Any future updates will be listed below
-
Authors
Yang, Mo https://orcid.org/0000-0002-8487-3866
Prestwood, Peri R. https://orcid.org/0009-0008-6453-4307
Passalacqua, Luiz F. M. https://orcid.org/0000-0002-5490-2427
Balaratnam, Sumirtha
Fullenkamp, Christopher R. https://orcid.org/0000-0002-9479-896X
Arney, J. Winston
Weeks, Kevin M. https://orcid.org/0000-0002-6748-9985
Ferre-D’Amare, Adrian https://orcid.org/0000-0003-4549-1619
Schneekloth, John S. Jr https://orcid.org/0000-0001-7459-783X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1ZIABC011585-08, 1ZIABC011585-08, 1ZIABC011585-08, 1ZIABC011585-08)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (ZIAHL006188, 1ZIAHL006188-08, 1ZIAHL006188-08)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM122532, R35 GM122532, R35 GM122532)
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 14 April 2025
First Online: 28 May 2025
Competing interests
: K.M.W. is an advisor to and holds equity in Ribometrix, ForagR Medicines and A-Form Solutions. The remaining authors declare no competing interests.
